Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VIT-2763 in non-transfusion dependent beta-thalassaemia
2019-002221-29Phase 2Completed
- Sponsor
- CSL Vifor
- Start
- Feb 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in beta thalassemia comparing VIT-2763 with Placebo (2 arms). Primary endpoint: Adverse events. Started Feb 2020; status: completed.
02
Drugs
vamifeport
03
Conditions
beta thalassemia
Beyond the preview
Go deeper on 2019-002221-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-002221-29.